Many studies have reported that CDKN2A deletion is associated with significantly shorter PFS and OS in both lower-grade glioma (LGG) and HGG (see Table 1) [48,65,86,87,88,89,90,91,92]. This evidence concerns the gene CDKN2A and glioma.